House of Lords Debate Applauds ‘Excellent Work’ of Genetics Team
News Jan 16, 2015
A debate in the House of Lords this week applauded ‘the excellent work carried out’ at Central Manchester University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ to improve the service for patients suffering from the genetic condition neurofibromatosis type 1 (NF1).
The debate highlighted that whilst centres, such as the one based at Saint Mary’s Hospital, Manchester, are running excellent clinical services, there is a national shortage of specialist clinics to work with patients, their families and health professionals to improve their care, and made an appeal to Government to improve the diagnosis and treatment of NF1.
The Manchester Centre for Genomic Medicine, based at Saint Mary’s Hospital, is currently one of two centres that lead the national response for NF1 in England.
Dr Sue Huson, Consultant Clinical Geneticist for the Neurofibromatosis Service at Manchester Centre for Genomic Medicine said:
“The NF1 service we run in Manchester continues to successfully manage our NF1 patients with very complex disease.
“Our service ensures that a diagnosis is made as early as possible, improves learning outcomes for children with NF1, and significantly improves their capacity to work as adults.
“We continue to develop the service and raise awareness of this relatively unknown condition, to improve outcomes for the 11,000+ people in England living with NF1.”
NF1 affects one person in every 2,500; therefore it is more common than Cystic Fibrosis and Muscular Dystrophy, but unlike these conditions, NF1 does not have the same high profile amongst the general population. The condition mainly affects the nervous system and the skin. Neurofibroma (benign tumours) can form on nerve coverings on or under the skin and can cause disfigurement.
Most people with NF1 experience skin changes and do not suffer from further health problems. However, some NF1 patients can have major health problems. These can include benign and malignant nerve tumours, abnormalities of bone, learning difficulties and some particular kinds of brain tumour. This can involve having to see a number of different specialists including Geneticists, Neurologists, Neurosurgeons, Plastic Surgeons and Ophthalmic (Eye) Surgeons.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019